Teva faces EU fine for disparaging rival multiple sclerosis medicine, sources say
Adds the European Commission comment, Teva did not immediately respond to request for comment, details
By Foo Yun Chee
BRUSSELS, Sept 10 (Reuters) -Teva TEVA.TA, the world's largest generic drugmaker, will be hit with an EU antitrust fine in the coming weeks for disparaging a rival product to its blockbuster multiple sclerosis medicine Copaxone, people with direct knowledge of the matter said on Tuesday.
The European Commission in 2022 charged the Israeli company with breaching EU antitrust rules, saying its anti-competitive practices included misusing the patent system to artificially extend Copaxone's patent and shield it from competition.
The EU competition enforcer's tough line underscores its concerns that such practices could stifle innovation in the pharmaceutical industry, with countries constrained by tight healthcare budgets.
The Commission declined to comment. Teva did not immediately respond to requests for comment.
The long-running case against Teva started with EU dawn raids in 2019 that led to the opening of an investigation in 2021.
Companies found guilty of EU antitrust violations risk fines of as much as 10% of their global annual turnover, although this is rare.
Teva and its subsidiary Cephalon were fined 60.5 million euros ($66.7 million) in 2020 for agreeing to delay a cheaper generic version of Cephalon's sleep disorder medicine, part of the EU's crackdown on so-called pay-for-delay deals between brand name drugmakers and their generic rivals.
($1 = 0.9073 euros)
Reporting by Foo Yun Chee
Editing by Mark Potter
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
